Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Methylphenidate N-of-1 series in adults with late-diagnosed PKU and ADHD
NL-OMON50968Withdrawn
- Sponsor
- Amsterdam University Medical Center
- Start
- Mar 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, double-blind trial of methylphenidate in attention deficit hyperactivity disorder (ADHD), sponsored by Amsterdam University Medical Center. Primary endpoint: Goal Attainment Scaling. Planned start Mar 2021; status: withdrawn.
02
Drugs
methylphenidate
03
Conditions
attention deficit hyperactivity disorder (ADHD)
Beyond the preview
Go deeper on NL-OMON50968.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON50968.